Consensus guidelines for the management of atopic dermatitis: An Asia–Pacific perspective


  • Funding sources: The publication of this paper was financially supported in part by Merck Sharp & Dohme (MSD). However, MSD was not involved in any aspect of the planning, writing or editing of this manuscript before or after its publication. The comments, views and conclusions set out in the manuscript represent those of the authors, independent of any input or influence from MSD.

  • Conflict of interest: None of the committee members has any financial interest in any of the companies whose products are discussed here.

Correspondence: Diana Rubel, FACD, MBBS, Woden Dermatology, Suite 10, Level 1, Corinna Chambers, 36-38 Corinna Street, Phillip, Canberra, ACT 2606, Australia. Email:


Atopic dermatitis (AD) is a relatively common disease in patients in the Asia–Pacific region. It presents a particular clinical challenge and requires careful clinical management. The chronic nature of AD characterized by flares, exacerbations and periods of quiescence requires a multipronged approach aimed at reducing itch, inflammation and the appearance of secondary lesions. In addition, varying levels of maintenance therapy may be required to avoid exacerbations. Survey data from the region indicate that there is significant variation across the Asia–Pacific with regard to current treatment practices. The management of AD may also be influenced by differing health-care systems, variable climate, access to medical care and cultural diversity. The current consensus guidelines have been developed to provide up-to-date and concise evidence- and experience-based recommendations directed towards general practitioners and general dermatologists in the Asia–Pacific region on the management of pediatric and adult AD.